Basic Stats
| LEI | 549300L1A5T19703RR64 |
| CIK | 1778016 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to I-Mab - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 25, 2025 |
Exhibit 99.1 I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee • Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of Directors • Research and Development Committee established to accelerate innovation and long-term growth • Dr. Ken Takeshita appoin |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| August 20, 2025 |
I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update • Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO GI 2025 showing 83% ORR at doses selected for ongoing expansion study • Topline data from planned dose expansion study of givastomig expected in Q1 2026 • Streng |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| August 11, 2025 |
Exhibit 99.1 I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers • Enrollment in the planned second dose expansion cohort completed ahead of expectations • Topline results expected in Q1 2026 • Positive Phase 1b dose escalation data presented at ESMO GI on July 2nd ROCKVILLE, MD, August 11, 20 |
|
| August 4, 2025 |
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares EX-99.1 Exhibit 99.1 I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares ROCKVILLE, MD, August 1, 2025 (Globe Newswire) – I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an underwritten offering in the United Sta |
|
| August 4, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of registrant’s principal executive offices) Indicate by check mark wheth |
|
| August 4, 2025 |
33,333,330 American Depositary Shares representing Ordinary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-286954 PROSPECTUS SUPPLEMENT (TO PROSPECTUS DATED MAY 15, 2025) I-MAB 33,333,330 American Depositary Shares representing Ordinary Shares We are offering 33,333,330 American Depositary Shares (“ADSs”). Each (10) ADSs represents twenty-three (23) ordinary shares, par value $0.0001 per share. The ADSs may be evidenced by Am |
|
| August 4, 2025 |
EX-1.1 Exhibit 1.1 I-Mab (a Cayman Islands exempted company) 33,333,330 American Depositary Shares Representing an Aggregate of 76,666,659 Ordinary Shares UNDERWRITING AGREEMENT August 1, 2025 Leerink Partners LLC as Representative of the several Underwriters c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, NY 10019 Ladies and Gentlemen: I-Mab, an exempted company incorpor |
|
| August 1, 2025 |
Exhibit (e) Rule 466 Certification The depositary, Citibank, N.A., represents and certifies the following: (i) That it previously had filed a registration statement on Form F-6 (Registration No. 333-235557), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Form F-6 Registration Statement; and (ii) That its ability |
|
| August 1, 2025 |
Exhibit (a) DEPOSIT AGREEMENT by and among I-MAB and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of January 22, 2020 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 “ADS Record Date” 1 Section 1.2 “Affiliate” 1 Section 1.3 “American Depositary Receipt(s)”, “ADR(s)” and “Receipt(s)” 1 Section 1.4 “American Deposi |
|
| August 1, 2025 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of registrant’s principal executive offices) Indicate by check mark wheth |
|
| August 1, 2025 |
As filed with the Securities and Exchange Commission on August 1, 2025 Registration No. |
|
| August 1, 2025 |
[Signature page on following page] Exhibit (d) August 1, 2025 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the Unit |
|
| July 17, 2025 |
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health Exhibit 99.1 I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health • Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications • Acquisition eliminates all royalty obligations and reduces future milestones for givastomig due to Bridge Health by I-Mab ROCKVILLE, MD, July 17, 2025 (G |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant f |
|
| July 17, 2025 |
Exhibit 1.1 EXECUTION VERSION CERTAIN INFORMATION (INDICATED BY “[***]”) HAS BEEN EXCLUDED FROM THIS AGREEMENT BECAUSE (I) SUCH INFORMATION IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL. EQUITY PURCHASE AGREEMENT BY AND AMONG I-MAB BIOPHARMA HONG KONG LIMITED, BRIDGE HEALTH BIO-TECH (SHANGHAI) CO., LTD., (桥健生物科技（上海）有限公司) SELLERS |
|
| July 11, 2025 |
Up to $50,000,000 American Depositary Shares representing Ordinary Shares 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-286954 AMENDMENT NO. 1 DATED JULY 11, 2025 To Prospectus Dated May 15, 2025 I-MAB Up to $50,000,000 American Depositary Shares representing Ordinary Shares This Amendment No. 1 to Prospectus (this “Amendment”) amends our prospectus, dated May 15, 2025 (the “Prospectus”), relating to the offer and sale of up to $21,000,000 of our American |
|
| July 11, 2025 |
A Phase Ib dose escalation study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with immunochemotherapy in HER2-negative, CLDN18.2-positive gastric, esophageal or gastro-esophageal junction adenocarcinoma Samuel J. Klempner, Farshid Dayyani, Jeremy Kratz, Sunnie Kim, Claire (Cong) Xu, Christoph M. Ahlers, Xuejun Liu, Jou-Ku Chung, Peter Sabbatini, Phillip A. Dennis, Sangmi L |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant f |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| July 11, 2025 |
Exhibit 99.1 I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to h |
|
| July 2, 2025 |
Transforming Potential into Reality I-Mab Biopharma July 2025 Transforming Potential into Reality I-Mab Biopharma July 2025 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewing or accessing the information contained in this |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant f |
|
| July 2, 2025 |
Exhibit 99.1 I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to h |
|
| July 2, 2025 |
A Phase Ib dose escalation study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, in combination with immunochemotherapy in HER2-negative, CLDN18.2-positive gastric, esophageal or gastro-esophageal junction adenocarcinoma Samuel J. Klempner, Farshid Dayyani, Jeremy Kratz, Sunnie Kim, Claire (Cong) Xu, Christoph M. Ahlers, Xuejun Liu, Jou-Ku Chung, Peter Sabbatini, Phillip A. Dennis, Sangmi L |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant f |
|
| June 26, 2025 |
Exhibit 99.1 I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CL |
|
| June 12, 2025 |
I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement Exhibit 99.1 I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement ROCKVILLE, MD, June 12, 2025 (GLOBE NEWSWIRE) - I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that on June 11, 2025 it received notification from The Nasdaq Stock Market L |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant f |
|
| June 2, 2025 |
Transforming Potential into Reality I-Mab Biopharma June 2025 Transforming Potential into Reality I-Mab Biopharma June 2025 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewing or accessing the information contained in this |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant f |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant fi |
|
| May 15, 2025 |
I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update Exhibit 99.1 I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update • Prioritization of givastomig as I-Mab’s lead program positions the Company for clinical progress • New givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona, Spain • Strong financial position supported by $168.6 million of cash and cash equivalents, |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant fi |
|
| May 2, 2025 |
Exhibit 4.7 I-MAB AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF I-MAB FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this “Agreement”), dated as of [•], between I-Mab, an exempted company incorporated in the Cayman Islands with limited liability and having its principal business office at 2440 Research Boulevard, Suite 400, Rockvill |
|
| May 2, 2025 |
As filed with the Securities and Exchange Commission on May 2, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 2, 2025 Registration No. |
|
| May 2, 2025 |
EX-1.2 Exhibit 1.2 I-MAB American Depositary Shares, each Ten (10) Representing Twenty-Three (23) Ordinary Shares ($0.0001 par value per share) SALES AGREEMENT May 2, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: I-Mab, an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), conf |
|
| May 2, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) I-Mab (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Equity Ordinary shares, par value $0. |
|
| May 2, 2025 |
I-Mab Dated as of , 20 Debt Securities Exhibit 4.4 I-Mab Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of , 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2.03 Denomination |
|
| May 2, 2025 |
Exhibit 4.6 I-MAB AND , AS WARRANT AGENT FORM OF ORDINARY SHARES WARRANT AGREEMENT DATED AS OF I-MAB FORM OF ORDINARY SHARES WARRANT AGREEMENT THIS ORDINARY SHARES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between I-Mab, an exempted company incorporated in the Cayman Islands with limited liability and having its principal business office at 2440 Research Boulevard, Suite 400, Rockvill |
|
| April 30, 2025 |
Exhibit 99.1 I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025 The ESMO Gastrointestinal Cancers Congress to be held July 2-5 in Barcelona ROCKVILLE, MD, April 30, 2025 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abst |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| April 4, 2025 |
Transforming Potential into Reality I-Mab Biopharma April 2025 Transforming Potential into Reality I-Mab Biopharma April 2025 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewing or accessing the information contained in thi |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| April 3, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-279842, 333-265684, 333-256603, 333-239871) of I-MAB of our report dated April 3, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting of I-MAB, which appears in this Fo |
|
| April 3, 2025 |
Exhibit 4.20 THE SYMBOL "[Redacted]" DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED AMENDMENT SIX TO COLLABORATION AGREEMENT This Amendment Six to Collaboration Agreement (the “Amendment Six”) is made on September 24, 2021 (the “Amendment Ef |
|
| April 3, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR |
|
| April 3, 2025 |
Exhibit 15.4 Harney Westwood & Riegels 3501 The Center 99 Queen's Road Central Hong Kong Tel: +852 5806 7800 Fax: +852 5806 7810 Date: 3 April 2025 057369.0006 I-Mab 2440 Research Boulevard, Suite 400 Rockville, MD 20850 United States Dear Sir or Madam I-Mab (the Company) We are attorneys-at-law qualified to practice in the Cayman Islands and have acted as Cayman Islands legal advisers to the Comp |
|
| April 3, 2025 |
Exhibit 4.10 Sublicense Agreement Party A: I-Mab Biopharma Hong Kong Limited Registered address: Suite 5105, 51/F, The Center, 99 Queen’s Road Central, Hong Kong Authorized representative: JINGWU ZHANG ZANG Party B: TJ Biopharma (Hangzhou) Co., Ltd. Registered address: No. 291, Fucheng Road, Xiasha Street, Hangzhou Economic and Technological Development Zone, Zhejiang Province Heda Pharma Valley C |
|
| April 3, 2025 |
Supplementary Agreement II to the Sublicense Agreement Exhibit 4.13 Supplementary Agreement II to the Sublicense Agreement This Supplementary Agreement II to the Sublicense Agreement (“this Supplementary Agreement”) is entered into by and between the following parties on May 9, 2022 (“Effective Date” of this Supplementary Agreement) in Shanghai, the People’s Republic of China: 1. I-MAB BIOPHARMA HONGKONG LIMITED, a company duly organized and existing |
|
| April 3, 2025 |
Exhibit 4.12 THE SYMBOL “[Redacted]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED FERRING INTERNATIONAL CENTER SA and I-MAB and I-MAB BIOPHARMA HONG KONG LIMITED AMENDED AND RESTATED LICENSE AND SUBLICENSE AGREEMENT Exhibit 4.12 INDEX 1. D |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| April 3, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of I-Mab (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Skelton, Chief F |
|
| April 3, 2025 |
CLINICAL TRIAL COLLABORATION AGREEMENT Exhibit 4.32 THE SYMBOL “[REDACTED]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CLINICAL TRIAL COLLABORATION AGREEMENT This Clinical Trial Collaboration Agreement (the “Agreement”) is made and entered into as of the date signed by the last Party to sign |
|
| April 3, 2025 |
Document Title: Code of Conduct Exhibit 11.1 POLICY Document Title: Code of Conduct Document Number: POL-0041 Revision Number: 02 Table of Contents Table of Contents 1 1. POLICY 2 2. HONEST AND ETHICAL CONDUCT. 3 3. LEGAL COMPLIANCE. 3 4. INSIDER TRADING. 3 5. REGULATORY COMPLIANCE. 4 6. INTERNATIONAL BUSINESS LAWS. 4 7. ANTITRUST. 4 8. ENVIRONMENTAL COMPLIANCE. 5 9. CONFLICTS OF INTEREST. 5 10. CORPORATE OPPORTUNITIES. 7 11. MA |
|
| April 3, 2025 |
AMENDMENT FOUR TO COLLABORATION AGREEMENT Exhibit 4.18 AMENDMENT FOUR TO COLLABORATION AGREEMENT This Amendment Four to Collaboration Agreement ("Amendment") is made on December 26, 2019 (the "Amendment Effective Date") by and between ABL Bio, having a business address at 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeongg-i-do, 13488, Republic of Korea ("ABL Bio") and I-MAB Biopharma Co., Ltd., having its business address |
|
| April 3, 2025 |
AMENDMENT FIVE TO COLLABORATION AGREEMENT Exhibit 4.19 AMENDMENT FIVE TO COLLABORATION AGREEMENT This Amendment Five to Collaboration Agreement (“Amendment”) is made on June 30, 2020 by and between ABL Bio lnc, having a business address at 16, Daewangpangyo-ro 712beon-gil, Bundang-gu. Seongnam-si. Gyeonggi-do. 13488. Republic of Korea (“ABL Bio”) and I-MAB Biopharma Co., Ltd., having its business address at Suite 802, OmniVision Park West |
|
| April 3, 2025 |
I-Mab Reports Full Year 2024 Financial Results and Provides Business Update Exhibit 99.1 I-Mab Reports Full Year 2024 Financial Results and Provides Business Update • Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025 • Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohort • |
|
| April 3, 2025 |
26/F HKRI Centre One, HKRI Taikoo Hui 288 Shimen Road (No.1), Shanghai 200041, P. R. China T: (86-21) 5298-5488 F: (86-21) 5298-5492 April 3, 2025 I-Mab 2440 Research Boulevard, Suite 400 Rockville, MD 20850 United States Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—Risks Related to Our Financial Position and Need for Ad |
|
| April 3, 2025 |
AMENDMENT TO COLLABORATION AGREEMENT Exhibit 4.15 AMENDMENT TO COLLABORATION AGREEMENT This Amendment to the COLLABORATION AGREEMENT (“Amendment”) is made effective as of November 5, 20218 (“Effective Date”), by and between: ABL Bio, having a business address at 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea (“ABL Bio”), and I-Mab, having its registered address at P.O. Box 31119, Gra |
|
| April 3, 2025 |
AMENDMENT THREE COLLABORATION AGREEMENT Exhibit 4.17 AMENDMENT THREE TO COLLABORATION AGREEMENT This Amendment Three to Collaboration Agreement (the “Amendment”) is made on May 24, 2019 (the “Amendment Effective Date”) by and between ABL Bio, having a business address at 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea (“ABL Bio”) and I-MAB Biopharma Co., Ltd., having its business address |
|
| April 3, 2025 |
AMENDMENT TWO TO COLLABORATION AGREEMENT Exhibit 4.16 AMENDMENT TWO TO COLLABORATION AGREEMENT This Amendment to the COLLABORATION AGREEMENT (“Amendment”) is made effective as of November 22, 2018 (“Effective Date”), by and between: ABL Bio, having a business address at 16, Daewangpangyo-ro 712 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, Republic of Korea (“ABL Bio”), and I-MAB Biopharma Co., Ltd., having its business address |
|
| April 3, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of I-Mab (the “Company”) on Form 20-F for the fiscal year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Xi-Yong (Sean) Fu, Chie |
|
| April 3, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.3 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-239871, No. 333-256603, No. 333-265684 and No. 333-279842) of I-Mab of our report dated April 30, 2024, except for the effects of discontinued operations discussed in Note 3, for the recast of the segment information discussed |
|
| April 3, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Xi-Yong (Sean) Fu, certify that: 1. I have reviewed this annual report on Form 20-F (this “report”) of I-Mab (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statemen |
|
| April 3, 2025 |
Exhibit 11.2 POLICY Document Title: Insider Trading Policy Document Number: POL-0019 Revision Number: 02 Table of Contents Table of Contents 1 1. PURPOSE 2 2. SCOPE 2 3. RESPONSIBILITY 2 4. ABBREVIATIONS AND DEFINITIONS 2 5. POLICY 4 6. DOCUMENT REVISION HISTORY 9 7. DOCUMENT(S) REPLACED 9 8. APPENDICES 9 Exhibit 11.2 POLICY Document Title: Insider Trading Policy Document Number: POL-0019 Revision |
|
| April 3, 2025 |
Supplementary Agreement to the Sublicense Agreement Exhibit 4.11 Supplementary Agreement to the Sublicense Agreement This Supplementary Agreement to the Sublicense Agreement (“this Supplementary Agreement”) is entered into by and between the following parties on December 16, 2021 in Shanghai, the People’s Republic of China: 1. I-MAB BIOPHARMA HONGKONG LIMITED, a company duly organized and existing under the laws of Hong Kong, China (“I-Mab Hong Kon |
|
| April 3, 2025 |
AMENDMENT SEVEN TO COLLABORATION AGREEMENT Exhibit 4.21 AMENDMENT SEVEN TO COLLABORATION AGREEMENT This AMENDMENT SEVEN TO COLLABORATION AGREEMENT (this “Amendment Seven”) is entered into on May 22, 2024 (the “Effective Date”) by and among ABL Bio, a company organized under the laws of the Republic of Korea having a business address at 16, Daewangpangyo-ro 712beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488, the Republic of Korea (“AB |
|
| April 3, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Joseph Skelton, certify that: 1. I have reviewed this annual report on Form 20-F (this “report”) of I-Mab (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement o |
|
| March 21, 2025 |
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement Exhibit 99.1 I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement ROCKVILLE, MD, March 21, 2025 (GLOBE NEWSWIRE)- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| March 7, 2025 |
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress Exhibit 99.1 I-Mab Announces Accelerated Givastomig Phase 1b Study Progress • Enrollment completed ahead of schedule in the first dose expansion cohort • Momentum continues with first patient dosed in the second expansion cohort • Topline results from the 40-patient dose expansion study expected in 1H 2026 • Phase 1b dose escalation data expected to be presented in 2H 2025 ROCKVILLE, MD, March 7, |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registra |
|
| February 27, 2025 |
Transforming Potential into Reality I-Mab Biopharma February 2025 Transforming Potential into Reality I-Mab Biopharma February 2025 Legal Disclaimer. |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registran |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registran |
|
| January 13, 2025 |
Transforming Potential into Reality I-Mab Biopharma January 2025 Transforming Potential into Reality I-Mab Biopharma January 2025 Legal Disclaimer. |
|
| January 8, 2025 |
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company’s American Depository Shares (ADSs) ROCKVILLE, MD, January 8, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U. |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registran |
|
| January 6, 2025 |
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program • Givastomig: a Claudin 18.2 (“CLDN18.2”) x 4-1BB bispecific antibody, will be the lead clinical program following the Company’s portfolio prioritization • The Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registran |
|
| December 3, 2024 |
Transforming Potential into Reality I-Mab Biopharma December 3, 2024 Transforming Potential into Reality I-Mab Biopharma December 3, 2024 Legal Disclaimer. |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registra |
|
| November 14, 2024 |
Transforming Potential into Reality I-Mab Biopharma November 14, 2024 Transforming Potential into Reality I-Mab Biopharma November 14, 2024 Legal Disclaimer. |
|
| November 14, 2024 |
I-Mab Reports Third Quarter 2024 Results Exhibit 99.1 I-Mab Reports Third Quarter 2024 Results • Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data • On track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025 • Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024 • Estimated cash runway into 2027, based on $184.4 million in cash and cash |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registra |
|
| November 6, 2024 |
6-K 1 seanfuceoappt11.6.20.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate |
|
| November 6, 2024 |
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer ROCKVILLE, MD, November 6, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U. |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registra |
|
| October 24, 2024 |
Transforming Potential into Reality I-Mab Biopharma October 24, 2024 Transforming Potential into Reality I-Mab Biopharma October 24, 2024 Legal Disclaimer. |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registran |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39173 I-MAB 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registr |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39173 I-MAB (Translation of registrant’s name into English) 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive off |
|
| September 16, 2024 |
I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 - Expanded Phase 1 monotherapy study of givastomig, a Claudin 18. |
|
| August 30, 2024 |
SECONDMENT AGREEMENT THIS SECONDMENT AGREEMENT (the “Agreement”) is made effective as of August 28, 2024 (the “Effective Date”) by and between I-MAB Biopharma US Limited, a Maryland corporation, with a principal place of business at 2440 Research Blvd, Suite 400, Rockville, MD 20850, USA (“I-Mab US”) and ABio-X Holdings, Inc. |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39173 I-MAB (Translation of registrant’s name into English) 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive office |
|
| August 28, 2024 |
Transforming Potential into Reality I-Mab Biopharma August 28, 2024 Transforming Potential into Reality I-Mab Biopharma August 28, 2024 Legal Disclaimer. |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39173 I-MAB (Translation of registrant’s name into English) 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive office |
|
| August 28, 2024 |
Transforming Potential into Reality I-Mab Biopharma 1H 2024 Results August 28, 2024 Transforming Potential into Reality I-Mab Biopharma 1H 2024 Results August 28, 2024 Disclaimer Legal Disclaimer. |
|
| August 28, 2024 |
I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates Exhibit 99.1 I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates • Completed divestiture of China operations • Uliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody) • Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4 |
|
| August 7, 2024 |
Exhibit 99.2 August 7, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by I-Mab (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to the Form 6-K of I-Mab dated August 7, 2024. We agree with the statements concerning our Firm contained therein. Very truly yours, /s |
|
| August 7, 2024 |
Exhibit 99.1 I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) Engagement is part of I-Mab’s commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, MD, August 7, 2024 – I-Mab (NASDAQ: IMAB) (“I-Mab”, the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential co |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39173 I-MAB (Translation of registrant’s name into English) 2440 Research Boulevard, Suite 400 Rockville, MD 20850 (Address of principal executive office |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number: 001-39173 I-MAB (Translation of registrant’s name into English) 2440 Research Blvd, Suite 400 Rockville, MD 20850 (Address of principal executive office) Indicat |
|
| July 15, 2024 |
I-Mab Announces Leadership Transitions Exhibit 99.1 I-Mab Announces Leadership Transitions ROCKVILLE, MD, July 15, 2024 – I-Mab (NASDAQ: IMAB) (the “Company” or “I-Mab”), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. Wei Fu as the Chairman of the Board of Directors. He succeeds Dr. Pamela M. Klein, who steps down from I-Mab’s Board of Directors and the Interim Chairpe |
|
| June 6, 2024 |
Exhibit 99.1 Transforming Potential into Reality I-Mab Biopharma June 5, 2024 2 Legal Disclaimer. This presentation has been prepared by I-Mab (the “Company”) solely for informational purposes. Certain of the information included herein was obtained from various sources, including certain third parties, and has not been independently verified by the Company. By viewing or accessing the information |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number: 001-39173 I-MAB (Translation of registrant’s name into English) 2440 Research Blvd, Suite 400 Rockville, MD 20850 (Address of principal executive office) Indicat |
|
| June 6, 2024 |
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer Exhibit 99.2 I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer ROCKVILLE, MD, June 6, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Offi |
|
| June 5, 2024 |
Exhibit 99.1 I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers · I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. · Colla |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June, 2024 Commission File Number: 001-39173 I-MAB (Translation of registrant’s name into English) 2440 Research Blvd, Suite 400 Rockville, MD 20850 (Address of principal executive office) Indicat |
|
| May 30, 2024 |
Exhibit 107 Calculation of Filing Fee Table S-8 (Form Type) I-MAB (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, par value $0. |
|
| May 30, 2024 |
As filed with the Securities and Exchange Commission on May 30, 2024 As filed with the Securities and Exchange Commission on May 30, 2024 Registration No. |
|
| May 30, 2024 |
Exhibit 99.1 i-mab 2024 OMNIBUS INCENTIVE PLAN (Adopted by the Board of Directors on May 30, 2024) Effective Date: May 30, 2024 TABLE OF CONTENTS Page Section 1. ESTABLISHMENT AND PURPOSE 1 Section 2. DEFINITIONS 1 (a) “Affiliate” 1 (b) “American Depositary Share” 1 (c) “Award” 1 (d) “Award Agreement” 1 (e) “Board of Directors” or “Board” 1 (f) “Cash-Based Award” 1 (g) “Change in Control” 1 (h) “C |
|
| May 23, 2024 |
Exhibit 99.1 I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitors - Phase 1 dose-escalation data demonstrated that ragistomig monothe |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2024 Commission File Number: 001-39173 I-MAB (Translation of registrant’s name into English) 2440 Research Blvd, Suite 400 Rockville, MD 20850 (Address of principal executive office) Indicate |
|
| April 30, 2024 |
Exhibit 97.1 I-MAB CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of I-Mab (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. 1. Definitions For purposes of this Policy |
|
| April 30, 2024 |
EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of I-Mab (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joseph Skelton, Chief Financial Officer of the Company, certify, pursuant to |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
|
| April 30, 2024 |
EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of I-Mab (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Raj Kannan, Chief Executive Officer of the Company, certify, pursuant to 18 U |
|
| April 30, 2024 |
Exhibit 15.3 Harney Westwood & Riegels 3501 The Center 99 Queen’s Road Central Hong Kong Tel: +852 5806 7800 Fax: +852 5806 7810 Date: 30 April 2024 057369.0005 I-Mab 天境生物 2440 Research Boulevard, Suite 400 Rockville, MD 20850 United States Dear Sir or Madam I-Mab 天境生物 (the Company) We are attorneys-at-law qualified to practice in the Cayman Islands and have acted as Cayman Islands legal advisers |
|
| April 30, 2024 |
Exhibit 15.1 26/F HKRI Centre One, HKRI Taikoo Hui, 288 Shimen Road (No. 1), Shanghai 200041, P.R. China T: (86-21) 5298-5488 F: (86-21) 5298-5492 [email protected] April 30, 2024 I-Mab 2440 Research Boulevard, Suite 400 Rockville, MD 20850 United States Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk Factors—Risks Related to Our F |
|
| April 30, 2024 |
EXHIBIT 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Raj Kannan, certify that: 1. I have reviewed this annual report on Form 20-F of I-Mab (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| April 30, 2024 |
EXHIBIT 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Joseph Skelton, certify that: 1. I have reviewed this annual report on Form 20-F of I-Mab (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in |
|
| April 30, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-239871, No. 333-256603 and No. 333-265684) of I-Mab of our report dated April 30, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. / |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39173 I-MAB 2440 Research Blvd, Suite 400 Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant files |
|
| April 2, 2024 |
I-Mab Announces Closing of the Divestiture of Business Operations in China Exhibit 99.1 I-Mab Announces Closing of the Divestiture of Business Operations in China ROCKVILLE, MD, April 2, 2024 – I-Mab (the “Company”) (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39173 I-MAB 2440 Research Blvd Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant files or will fi |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39173 I-MAB 2440 Research Blvd Rockville, MD 20850 (Address of principal executive offices) Indicate by check mark whether the registrant files or will fi |
|
| March 15, 2024 |
I-Mab Reports Full Year 2023 Financial Results and Business Update Exhibit 99.1 I-Mab Reports Full Year 2023 Financial Results and Business Update · Recently announced agreement to divest assets and business operations in China marks an important milestone for the Company; the transaction is expected to close by the end of March 2024 · Uliledlimab (CD73 antibody) on track to file an IND in combination with chemotherapy and checkpoint inhibitors for patients with |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executiv |
|
| February 13, 2024 |
IMAB / I-Mab - Depositary Receipt (Common Stock) / GIC Private Ltd Passive Investment Page 1 of 5 CUSIP No. 44975P 103 SCHEDULE 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) * I-MAB (Name of Issuer) Ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 44975P 103 ** (CUSIP Number) December 31, 2023 (Date of the Event Which Requires Filing of this Statemen |
|
| February 9, 2024 |
IMAB / I-Mab - Depositary Receipt (Common Stock) / Zang Jingwu Zhang - SC 13G/A Passive Investment SC 13G/A 1 tm245056d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* I-MAB (Name of Issuer) Ordinary shares, par value of $0.0001 per share (Title of Class of Securities) 44975P 103** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal execu |
|
| February 7, 2024 |
I-Mab Biopharma (Hangzhou) Co., Ltd. INVESTMENT AGREEMENT February 6, 2024 TABLE OF CONTENTS Exhibit 99.4 English Translation I-Mab Biopharma (Hangzhou) Co., Ltd. INVESTMENT AGREEMENT February 6, 2024 TABLE OF CONTENTS 1 Definitions 3 2 Capital Increase 6 3 Conditions Precedent to the Closing 6 4 Closing and Related Matters 8 5 Representations and Warranties 11 6 Arrangements for the Transitional Period 18 7 Addtional Agreements and Covenants 20 8 Liability for Breach of Contract and Inde |
|
| February 7, 2024 |
Exhibit 99.3 English Translation Equity Transfer Agreement of I-Mab Biopharma (Hangzhou) Co., Ltd. February 6, 2024 Equity Transfer Agreement of I-Mab Biopharma (Hangzhou) Co., Ltd. This Equity Transfer Agreement of I-Mab Biopharma (Hangzhou) Co., Ltd. (this “Agreement”) is entered into on February 6, 2024 (the “Execution Date”) in the People’s Republic of China (the “PRC”) by and among: 1. I-Mab |
|
| February 7, 2024 |
Exhibit 99.2 English Translation THE SYMBOL “[REDACTED]” DENOTES PLACES WHERE CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (1) NOT MATERIAL, AND (2) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Equity Transfer Agreement of I-Mab Biopharma Co., Ltd. February 6, 2024 Equity Transfer Agreement of I-Mab Biopharma Co., Ltd. This Equity Transfer Agreement |
|
| February 7, 2024 |
I-Mab Biopharma (Hangzhou) Co., Ltd. SHAREHOLDERS’ AGREEMENT February 6, 2024 TABLE OF CONTENTS Exhibit 99.5 English Translation I-Mab Biopharma (Hangzhou) Co., Ltd. SHAREHOLDERS’ AGREEMENT February 6, 2024 TABLE OF CONTENTS Article I INFORMATION AND INSPECTION RIGHTS - 6 - Article II LOCK-UP - 7 - Article III INVESTOR PREFERENTIAL RIGHTS - 8 - Article IV CORPORATE GOVERNANCE - 16 - Article V LIABILITIES AND INDEMNIFICATION - 18 - Article VI EFFECTIVENESS, AMENDMENT AND TERMINATION - 19 - Ar |
|
| February 7, 2024 |
I-Mab Signs Agreement to Divest its Assets and Business Operations in China Exhibit 99.1 I-Mab Signs Agreement to Divest its Assets and Business Operations in China · Agreement marks an important milestone to advance the Company’s intent to become a U.S.-based biotech · Agreement provides for a strategic focus in advancing I-Mab’s potential of differentiated oncology clinical assets and builds shareholder value by streamlining the operating model, reducing operational cos |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal execu |
|
| December 1, 2023 |
IMAB / I-Mab - ADR / T Investment Ltd - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No.)* I-MAB (Name of Issuer) Ordinary Shares (Title of Class of Securities) 44975P1030 (CUSIP Number) To Tony Chin T INVESTMENT LIMTED Flat B, 4th Floor, Haven |
|
| October 10, 2023 |
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 Exhibit 99.1 I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 - Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response and two unconfirmed partial responses; maximum tolerated dose not yet reached - Patent rights secured for TJ-L14B/ABL503 in Eurasia until 2039 ROCKVILLE, MD, U.S. |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal execut |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal exec |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executi |
|
| August 17, 2023 |
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates Exhibit 99.1 I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates · Significant progress made year-to-date on key clinical assets: - Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 - Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including patients with low levels of Cla |
|
| August 7, 2023 |
I-Mab 55th Floor, New Bund Center, 555 West Haiyang Road Pudong District, Shanghai 200124 People’s Republic of China August 7, 2023 VIA EDGAR Mr. |
|
| June 30, 2023 |
IMAB / I-Mab - ADR / HILLHOUSE CAPITAL ADVISORS, LTD. - I-MAB Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* I-MAB (Name of Issuer) Ordinary Shares (Title of Class of Securities) 44975P103** (CUSIP Number) Richard A. Hornung HHLR Advisors, Ltd. Office #122, Windward 3 Building, Regatta Office Park West Bay Road, Grand Cayman Cayman Islands, KY1-9006 + 345-749-8643 With a c |
|
| June 22, 2023 |
I-Mab Announces the Appointment of Raj Kannan as CEO Exhibit 99.1 I-Mab Announces the Appointment of Raj Kannan as CEO GAITHERSBURG, MD. and SHANGHAI, CHINA, June 22, 2023 — I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced the appointment of Mr. Raj Kannan as the Company’s new Chief Executive Office |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executive |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executive |
|
| May 26, 2023 |
Exhibit 99.1 I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023 - Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients’ immune system against cancer cells. - In newly diagnosed patients who were not eligible for or declined chem |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
|
| May 1, 2023 |
Exhibit 15.1 26/F HKRI Centre One, HKRI Taikoo Hui, 288 Shimen Road (No. 1), Shanghai 200041, P.R. China T: (86-21) 5298-5488 F: (86-21) 5298-5492 [email protected] May 1, 2023 I-Mab 55th Floor, New Bund Center 555 West Haiyang Road Pudong District, Shanghai People’s Republic of China Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3. Key Information—D. Risk |
|
| May 1, 2023 |
Exhibit 4.22 THE SYMBOL “[REDACTED]” DENOTES PLACES WHERE CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (1) NOT MATERIAL, AND (2) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. August 15, 2022 I-Mab Biopharma Co., Ltd. 天境生物科技(上海)有限公司 Suite 802, West Tower, OmniVision 88 Shangke Road, Pudong District Shanghai, 201210 P.R. China Attn: Legal I-Mab Biopharm |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executive |
|
| May 1, 2023 |
Exhibit 15.3 Harney Westwood & Riegels 3501 The Center 99 Queen’s Road Central Hong Kong Tel: +852 5806 7800 Fax: +852 5806 7810 Date: 1 May 2023 057753.0003 I-Mab 天境生物 55th Floor, New Bund Center 555 West Haiyang Road Pudong District, Shanghai People’s Republic of China Dear Sir or Madam I-Mab 天境生物 (the Company) We are attorneys-at-law qualified to practice in the Cayman Islands and have acted as |
|
| May 1, 2023 |
Exhibit 99.1 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 · Strategic reprioritization of the Company’s pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus · Thirteen key |
|
| May 1, 2023 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-239871, No. 333-256603 and No. 333-265684) of I-Mab of our report dated May 1, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. /s/P |
|
| May 1, 2023 |
I-Mab Biopharma (Hangzhou) Co., Ltd. Shareholders Agreement July 16, 2022 Exhibit 4.24 English translation I-Mab Biopharma (Hangzhou) Co., Ltd. Shareholders Agreement July 16, 2022 Table of Contents Article 1 Information and Inspection Rights - 5 - Article 2 Equity Lockup - 6 - Article 3 Investors’ Preferred Rights - 7 - Article 4 Corporate Governance - 15 - Article 5 Dissolution of Act in Concert - 17 - Article 6 Liability for Breach of Contract; Indemnification - 18 - |
|
| May 1, 2023 |
I-Mab Biopharma (Hangzhou) Co., Ltd. Investment Agreement July 16, 2022 Exhibit 4.23 English translation I-Mab Biopharma (Hangzhou) Co., Ltd. Investment Agreement July 16, 2022 Table of Contents Article 1 Definitions 4 Article 2 This Capital Increase 7 Article 3 Closing Conditions 7 Article 4 Closing and Related Matters 9 Article 5 Representations and Warranties 13 Article 6 Transitional Period Covenants 20 Article 7 Other Agreements and Covenants 22 Article 8 Liabili |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executive |
|
| May 1, 2023 |
EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of I-Mab (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard Yeh, Interim Chief Financial Officer of the Company, certify, pursuan |
|
| May 1, 2023 |
EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of I-Mab (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrew Zhu, Acting Chief Executive Officer of the Company, certify, pursuant |
|
| May 1, 2023 |
EXHIBIT 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Richard Yeh, certify that: 1. I have reviewed this annual report on Form 20-F of I-Mab (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lig |
|
| May 1, 2023 |
EXHIBIT 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Andrew Zhu, certify that: 1. I have reviewed this annual report on Form 20-F of I-Mab (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| April 25, 2023 |
6-K 1 tm2313658d26k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of Chi |
|
| April 25, 2023 |
Exhibit 99.1 I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China GAITHERSBURG, MD. and SHANGHAI, China – April 24, 2023 – I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executiv |
|
| April 25, 2023 |
I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon Exhibit 99.1 I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon - Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute - Tribunal completely denied Tracon’s groundless damages claim of over $200 million relating to I-Mab’s next-generation bi-specific antibody assets and awarded no damages to Tracon - Tri |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executiv |
|
| March 31, 2023 |
Exhibit 99.1 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 · Strategic reprioritization of the Company’s pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus · Thirteen key |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39173 I-MAB 55th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal executiv |
|
| February 15, 2023 |
IMAB / I-MAB / CBC Investment I-Mab Ltd - SC 13G/A Passive Investment SC 13G/A 1 tm236297d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* I-MAB (Name of Issuer) Ordinary Shares, par value US$0.0001** American Depositary Shares (Title of Class of Securities) 44975P103** (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Sta |
|
| February 8, 2023 |
IMAB / I-MAB / Zang Jingwu Zhang - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* I-MAB (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) 44975P103** (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 7, 2023 |
IMAB / I-MAB / GIC Private Ltd Passive Investment SC 13G/A 1 sch13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) * I-MAB (Name of Issuer) Ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 44975P 103 ** (CUSIP Number) December 31, 2022 (Date of the Event Which Requires Filing of this Statement) Check the appropriate |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 - Commission File Number: 001-39173 - I-MAB 55th – 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of prin |
|
| November 10, 2022 |
Exhibit 99.3 ? RECENT DEVELOPMENTS The following section sets forth our key recent developments since the filing of our annual report on Form 20-F for the fiscal year ended December 31, 2021, which updates and supplements the disclosure contained therein, and should be read in conjunction with such annual report, our Registration Statement on Form F-3 filed with the SEC on February 5, 2021 and the |
|
| November 10, 2022 |
For the Six Months Ended June 30, Exhibit 99.2 ? Six Months Ended June 30, 2022 Compared to Six Months ended June 30, 2021 Revenues Our revenues increased from RMB17.8 million for the six months ended June 30, 2021 to RMB51.9 million (US$7.7 million) for the six months ended June 30, 2022. Revenues generated for the six months ended June 30, 2022, consisted of revenues recognized in connection with the strategic collaboration with |
|
| November 10, 2022 |
Table of Contents Exhibit 99.1 I-Mab INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2021 and 2022 Page Consolidated Balance Sheet as of December 31, 2021 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2022 F-2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Lo |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Address of princip |
|
| September 13, 2022 |
EX-99.1 2 tm2225761d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022 • Lemzoparlimab combined with AZA showed encouraging clinical response in higher-risk MDS patients • For patients received initial dose over 3 months, the ORR is 80.6% and for patien |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Address of princip |
|
| September 13, 2022 |
Exhibit 99.2 I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome GAITHERSBURG, MD. and SHANGHAI, China ? September 13, 2022 ? I-Mab (the ?Company?) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel bio |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Address of principal |
|
| August 30, 2022 |
Exhibit 99.1 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2022 - Seven key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab, and TJ-CD4B - Lemzoparlimab is on track for Phase 3 study for 1L MDS - Amendment to the global partnership with AbbVie for certain new CD47 antibodies c |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Address of principal |
|
| June 17, 2022 |
Exhibit 10.1 I-MAB 天境生物 2022 SHARE INCENTIVE PLAN ARTICLE I. PURPOSE The purpose of this 2022 Share Incentive Plan (the “Plan”) is to promote the success and enhance the value of I-MAB 天境生物, an exempted company incorporated under the laws of the Cayman Islands (the “Company”), by linking the personal interests of Service Providers to those of the Company’s shareholders and by providing such indivi |
|
| June 17, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) I-MAB (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, par value $0. |
|
| June 17, 2022 |
As filed with the Securities and Exchange Commission on June 17, 2022 As filed with the Securities and Exchange Commission on June 17, 2022 Registration No. |
|
| June 13, 2022 |
IMAB / I-MAB / Infini Master Fund - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* I-MAB (Name of Issuer) Sponsored ADS (Title of Class of Securities) 44975P 103 (CUSIP Number) May 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? |
|
| May 27, 2022 |
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab Exhibit 99.1 I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab - Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity - Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort - Results indicate CD73 expression correlates with clinical |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Address of principal exe |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Address of principal exe |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39173 I-MAB 55th – 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of China (Address of principal exe |
|
| May 5, 2022 |
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act Exhibit 99.1 I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act SHANGHAI and GAITHERSBURG, MD. May 5, 2022 – I-Mab (“I-Mab” or the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today provided updates on its status under the Holding Foreign Companies Accountable A |
|
| April 29, 2022 |
EX-15.1 8 d231634dex151.htm EX-15.1 EXHIBIT 15.1 April 29, 2022 I-Mab 55th – 56th Floor, New Bund Center 555 West Haiyang Road Pudong District, Shanghai People’s Republic of China Dear Sir/Madam: We hereby consent to the reference of our name under the headings “Item 3.D. Key Information—Risk Factors—Risks Related to Doing Business in China” and “Item 10. Additional Information—E. Taxation—PRC Tax |
|
| April 29, 2022 |
EX-12.2 EXHIBIT 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, John Long, certify that: 1. I have reviewed this annual report on Form 20-F of I-Mab (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| April 29, 2022 |
EX-12.1 EXHIBIT 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Jingwu Zhang Zang, certify that: 1. I have reviewed this annual report on Form 20-F of I-Mab (the “Company”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statement |
|
| April 29, 2022 |
Consent of Harney Westwood & Riegels EXHIBIT 15.3 April 29, 2022 I-Mab ???? 55th ? 56th Floor, New Bund Center 555 West Haiyang Road Pudong District, Shanghai People?s Republic of China Dear Sir/Madam: I-MAB ???? (the Company) We are attorneys-at-law qualified to practice in the Cayman Islands and have acted as Cayman Islands legal advisers to the Company in connection with the filing by the Company with the United States Securities |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021. OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
|
| April 29, 2022 |
Exhibit 4.24 THE SYMBOL ?[REDACTED]? DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS (1) NOT MATERIAL AND (2) THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Exclusive Development, Manufacture, and Sales Cooperation Agreement This Exclusive Development, Manufacture, and Sales Cooperation Agreement (the ?Agreement?) is executed on |
|
| April 29, 2022 |
EX-13.1 EXHIBIT 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of I-Mab (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jingwu Zhang Zang, Chief Executive Officer of the Company, certify, p |
|
| April 29, 2022 |
EX-13.2 EXHIBIT 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of I-Mab (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Long, Chief Financial Officer of the Company, certify, pursuant |
|
| April 29, 2022 |
Consent of PricewaterhouseCoopers Zhong Tian LLP EXHIBIT 15.2 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-239871 and No. 333-256603) and Form F-3 (No. 333-252793) of I-Mab of our report dated April 29, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in thi |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Add |
|
| April 28, 2022 |
Exhibit 99.1 I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer ? Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO ? Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab?s innovative pipeline as CM |
|
| April 28, 2022 |
Exhibit 99.1 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 ? Financial results demonstrate strong fundamentals ? Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab ? Seven business development deals, including a US$315M strategic commercial partnersh |
|
| April 28, 2022 |
6-K 1 d335653d6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39173 I-MAB 55th – 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People’s Republic of |
|
| March 31, 2022 |
Up to 16,412,990 American Depositary Shares Representing up to 37,749,950 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252793 Prospectus Supplement (To Prospectus Dated February 5, 2021) Up to 16,412,990 American Depositary Shares I-MAB Representing up to 37,749,950 Ordinary Shares The selling shareholders identified in this prospectus supplement may offer, from time to time, up to 37,749,950 ordinary shares, including ordinary shares represen |
|
| March 31, 2022 |
Exhibit 107 Calculation of Filing Fee Table 424(b)(3) (Form Type) I-MAB (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, par value US$0. |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Address of principal e |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Add |
|
| March 31, 2022 |
Exhibit 99.1 I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment SHANGHAI and GAITHERSBURG, MD. March 31, 2022 ? I-Mab (the ?Company?) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company?s key shareholders including CBC Group ( |
|
| March 31, 2022 |
Exhibit 99.1 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 ? Financial results demonstrate strong fundamentals ? Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab ? Seven business development deals, including a US$315M strategic commercial partnersh |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39173 I-MAB 55th ? 56th Floor, New Bund Center, 555 West Haiyang Road, Pudong District Shanghai, 200124 People?s Republic of China (Address of principal e |
|
| March 29, 2022 |
Exhibit 99.1 I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 ? Financial results demonstrate strong fundamentals ? Twenty key clinical milestones achieved year-to-date, including positive data readouts for lemzoparlimab, uliledlimab and felzartamab ? Seven business development deals, including a US$315M strategic commercial partnersh |
|
| March 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal executiv |
|
| March 4, 2022 |
Exhibit 99.1 I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer SHANGHAI, China and GAITHERSBURG, MD. March 3, 2022 ? I-Mab (the ?Company?) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the U. |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| February 14, 2022 |
IMAB / I-MAB / GIC Private Ltd Passive Investment SCHEDULE 13G/A CUSIP No. 44975P 103 Page 1 of 5 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) * I-MAB (Name of Issuer) Ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 44975P 103 ** (CUSIP Number) December 31, 2021 (Date of the Event Which Requires Filing of this St |
|
| February 11, 2022 |
IMAB / I-MAB / Zang Jingwu Zhang - SCHEDULE 13G AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* I-MAB (Name of Issuer) Ordinary Shares, par value of $0.0001 per share (Title of Class of Securities) 44975P103** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 11, 2022 |
Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary s |
|
| January 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execut |
|
| January 28, 2022 |
I-Mab’s Announcement on Unusual Price Movement Exhibit 99.1 I-Mab?s Announcement on Unusual Price Movement SHANGHAI, China, and GAITHERSBURG, MD. ? I-Mab (the ?Company?) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics. The Company has noted the recent unusual fluctuations in the price and trading volume of the American depositary shares (the ?ADSs?) of |
|
| January 25, 2022 |
IMAB / I-MAB / CBC Investment I-Mab Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* I-MAB (Name of Issuer) Ordinary Shares, par value $0.0001** American Depositary Shares (Title of Class of Securities) 44975P103** (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| January 14, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252793 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Amount to be Registered(2) Proposed Maximum Offering Price per Share(3) Proposed Maximum Aggregate Offering Price(3) Amount of Registration Fee Ordinary shares, par value US$0.0001 per share 1,036,541 US$16.42 US$17,017,299.2 US$1,577. |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| December 21, 2021 |
Exhibit 99.1 I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization ? New appointments as part of the Company?s strategic development plans to accelerate transformation towards commercialization ? Dr. Andrew Zhu, an internationally renowned oncologist, appointed as President and board director to lead the Company?s R&D orga |
|
| December 15, 2021 |
Exhibit 99.1 I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021 - Positive clinical activity was observed in heavily pretreated patients who had progressed on prior Anti-CD20 therapies SHANGHAI, China and GAITHERSBURG, MD, December 14, 2021 ? I-Mab (the ?Company?) (Nasdaq: IMAB), a clinical stage biopharma |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| December 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| December 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| December 8, 2021 |
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited Exhibit 99.1 I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited SHANGHAI, China ? December 7, 2021 ? I-Mab (the ?Company?) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Board of Directors of the Company (the ?Board?) approved a motion t |
|
| December 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| December 6, 2021 |
Exhibit 99.1 I-Mab Announces First Two Patients Dosed in U.S. Phase 2 Combination Trial of Uliledlimab with Atezolizumab in Patients with Selected Advanced Solid Tumors SHANGHAI, CHINA, and GAITHERSBURG, MD. December 3, 2021? I-Mab (the ?Company?) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today annou |
|
| November 26, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252793 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Amount to be Registered(2) Proposed Maximum Offering Price per Share(3) Proposed Maximum Aggregate Offering Price(3) Amount of Registration Fee Ordinary shares, par value US$0.0001 per share 1,000,293 US$27.87 US$27,878,165.9 US$2,584. |
|
| November 12, 2021 |
I-Mab INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 I-Mab INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2020 and 2021 Page Consolidated Balance Sheet as of December 31, 2020 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2021 1 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Month |
|
| November 12, 2021 |
Exhibit 99.3 RISK FACTORS The following section sets forth our risk factors, which have been updated and/or supplemented since the filing of our annual report on Form 20-F for the fiscal year ended December 31, 2020 and should be read in conjunction with such annual report, our Registration Statement on Form F-3 filed with the SEC on February 5, 2021 and the related prospectus supplement filed wit |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| November 12, 2021 |
I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa EX-99.2 3 d225238dex992.htm EX-99.2 Exhibit 99.2 I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa • The partnership brings together the strengths of an innovative global biotech and a domestic leading pharmaceutical company specialized in and committed to pediatric medicines to accelerate the commercialization of eftansomatropin alfa • Jumpcan will pay I-Mab for |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| November 12, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252793 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered(1) Amount to be Registered(2) Proposed Maximum Offering Price per Share (3) Proposed Maximum Aggregate Offering Price (3) Amount of Registration Fee Ordinary shares, par value US$0.0001 per share 958,341 US$26.52 US$25,415,203 US$2,355.99 |
|
| November 12, 2021 |
Exhibit 99.2 Six Months Ended June 30, 2021 Compared to Six Months ended June 30, 2020 Revenues Our revenues generated from licensing and collaboration increased from nil for the six months ended June 30, 2020 to RMB17.8 million (US$2.8 million) for the six months ended June 30, 2021. Our revenues generated for the six months ended June 30, 2021 solely consisted of the revenue recognized in connec |
|
| November 12, 2021 |
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC Exhibit 99.1 I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC ? Preclinical data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 demonstrate targeted safety profile and enhanced anti-tumor activity ? Both studies are undergoing phase 1 clinical trials in the United States SHANGHAI, China, GAITHERSBURG, MD. and SEONGNAM, South Korea. November 9, 2021 ? I-Mab (Nas |
|
| November 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39173 I-MAB Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District Shanghai, 201210 People?s Republic of China (Address of principal execu |
|
| November 5, 2021 |
Exhibit 99.2 Lemzoparlimab, a Differentiated Anti-CD47 Antibody in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin?s Lymphoma: Initial Clinical Results Program: Oral and Poster Abstracts Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Clinical Trials, Clinical Research Monda |
|
| November 5, 2021 |
Exhibit 99.1 I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins?s Lymphoma at ASH 2021 ? Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie ? Initial clinical results of lemzoparlimab in combination with rituximab in NHL will be presented at the ASH 2021 Annual Meeting ? I-Mab to |
